Following Anthropic's (ANTHRO) product event, Wedbush (IVES) said that competition risk to software is overblown.
Septerna is poised for a pivotal catalyst with upcoming Phase 1 data for SEP-631, targeting mast cell-driven diseases via ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results